Medical Advocates
Nevirapine (Viramune)
 
Journal Citations: Adverse Events

General Reports
Cardiovascular Disorders
Cutaneous Disorders
 Hepatic Disorders
 Hypersensitivity
Mental Disorders
 Meningoencephalitis
 Metabolic Disorders
Renal Disorders
 Oral Disorders
 Stevens-Johnson Syndrome/Toxic Epidermal Necrosis 
 
NVP Main Page Journal Main Page Main New/Newsworthy  Home Page
Last Update:  August 25, 2017
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
Nevirapine induced mitochondrial dysfunction in HepG2 cells.
 Paemanee A, Sornjai W, Kittisenachai S,  et al
 Sci Rep. 2017 Aug 23;7(1):9194.
Abstract

Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells.
Jensen K, Bikas AD, Patel A,  et al
Endocr Relat Cancer. 2017 Jan 30.
Abstract

Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.
 Marinho AT, Rodrigues PM, Caixas U,  et al  J
 Antimicrob Chemother. 2014 Feb;69(2):476-82.
 Abstract

Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
 McIlroy D, Allavena C, Rodallec A,  et al
J Med Virol. 2013 Sep 23.
 Abstract

Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.
 Marinho AT, Rodrigues PM, Caixas U,  et al
J Antimicrob Chemother. 2013 Sep 19
 Abstract

FULL-TEXT ARTICLE
 DRESS Syndrome due to Nevirapine Treated with Methylprednisolone.
 Pott Junior H, Gosuen GC, Gales AC.
Case Rep Med. 2013;2013:269501
 Paper

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
 Shubber Z, Calmy A, Andrieux-Meyer I, et al
AIDS. 2013 Jan 22. [
 Abstract

Long-term therapy with nevirapine and tropism.
 Moling O, Andreis S, Bressan S,et al
J Int AIDS Soc. 2012 Nov 11;15(6):18157
 Abstract

Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: an Exploratory Study of the TRIANON ANRS 081 Trial.
 Gozalo C, Gérard L, Loiseau P,  et al
Basic Clin Pharmacol Toxicol. 2011 Aug 9.
Abstract

Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina.
 Bottaro EG, Huberman MJ, Iannella Mdel C, et al
J Int Assoc Physicians AIDS Care 2010 Sep-Oct;9(5):306-12.
 Abstract

Amino Acid Adduct Formation by the Nevirapine Metabolite, 12-Hydroxynevirapine
A Possible Factor in Nevirapine Toxicity.
 Antunes AM, Godinho AL, Martins IL,  et al
Chem Res Toxicol. 2010 Apr 14.
 Abstract

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing
antiretroviral therapy.
Kesselring AM, Wit FW, Sabin CA, et al
AIDS. 2009 May 29.
Abstract

Nevirapine Toxicity in Non-HIV Cancer Patients.
 Landriscina M, Fabiano A, Lombardi V, et al 
Chemotherapy. 2008 Oct 2;54(6):475-478.
 Abstract
 
Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens : CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
 Torti C, Costarelli S, De Silv
 Abstract
 
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant
women.
Phanuphak N, Apornpong T, Teeratakulpisarn S, et al
HIV Med. 2007 Sep;8(6):357-66.
 Abstract
 
Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4
count.
Tansuphaswadikul S, Aung SE, Phonrat B, et al
Asian Pac J Allergy Immunol. 2007 Jun-Sep;25(2-3):147-54.
 Abstract

Nevirapine toxicity.
 Taiwo BO.
 Int J STD AIDS. 2006 Jun;17(6):364-70.
 Abstract
Cardiovascular Disorders
       
 
Nevirapine and cardiovascular risk.
 Parienti JJ, Verdon R.  
Med Mal Infect. 2010 Apr 28.
Abstract

FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
van Leth F, Phanuphak P, Stroes E, et al
PLOS Vol2 Issue 9 Sep 2005
 Paper
Cutaneous
       
 
Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
 Tseng YT, Yang CJ, Chang SY, et al
Int J Infect Dis. 2014 Oct 10
 Abstract

FULL-TEXT ARTICLE
Nevirapine induced toxic epidermal necrolysis and non-Hodgkin lymphoma in a Human Immunodeficiency Virus positive patient.
Budamakuntla L, Loganathan E, Suryanarayan S, et al
 Indian Dermatol Online J. 2014 Apr;5(2):179-81
 Paper

Rash and hepatitis within days of starting a new antiretroviral regimen: Nevirapine hypersensitivity, secondary syphilis or both?
 Saxon CJ, Helbert MR, Komolafe AJ, Higgins SP.
 Int J STD AIDS. 2013 Aug 8.
 Abstract

Identification of 'Danger' Signals in Nevirapine-Induced Skin Rash.
 Zhang X, Sharma AM, Uetrecht J.
Chem Res Toxicol. 2013 Aug 15
 Abstract

FULL-TEXT PDF ARTICLE
 Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.
 Ratanasuwan W, Jariyasethpong T, Anekthananon T,  et al
 Open AIDS J. 2012;6:266-73. 
Paper

FULL-TEXT DOCUMENT
HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients.
Umapathy S, Pawar A, Bajpai S,
 J Pharmacol Pharmacother. 2011 Apr;2(2):114-5.
 Letter

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
 Yuan J, Guo S, Hall D, et al
AIDS. 2011 Apr 18.
Abstract

HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.
 Likanonsakul S, Rattanatham T, Feangvad S,  et al 
AIDS Res Ther. 2009 Oct 21;6(1):22.
 Abstract

A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients: In Settings of Low CD4 Cell Counts and Resource Limitation.
Kiertiburanakul S, Sungkanuparph S, Malathum K 
Open AIDS J. 2009 Jul 8;3:24-30.
 Abstract

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in
HIV-infected Thai patients.
 Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al  
Pharmacogenet Genomics. 2009 Dec 19
 Abstract
 
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
 Vitezica ZG, Milpied B, Lonjou C, et al 
AIDS. 2008 Feb 19;22(4):540-1.
Abstract
 
Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/muL.
 Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al 
Int J STD AIDS. 2007 Nov;18(11):782-786.
 Abstract
 
Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
 Daniel OJ, Krain AB, Ogun SA, Odusoga OL, Boyle BA.  
J Natl Med Assoc. 2005 Dec;97(12):1719-21.
 Abstract
 
Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG).
 Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P.
J Drugs Dermatol. 2005 Jul-Aug;4(4):510-3
 Abstract
 
Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz.
Hartmann M, Brust J, Schuster D, et al 
Hautarzt. 2005 Feb 23
 Abstract
 
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
 Ananworanich J, Moor Z, Siangphoe U, et a;
AIDS. 2005 Jan 28;19(2):185-192
 Abstract
 
Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine.
 Claes P, Wintzen M, Allard S, 
Eur J Intern Med. 2004 Jul;15(4):255-258.
Abstract
 
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy:results of the viramune-zyrtec double-blind, placebo-controlled trial.
 Launay O, Roudiere L, Boukli N, et al   
Clin Infect Dis. 2004 Apr 15;38(8):e66-7|
 Abstract
 
Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non-HIV-Infected Individuals.
 Patel SM, Johnson S, Belknap SM, et al 
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 120-125
 Abstract
 
Incidence and risk factors for nevirapine-associated rash.
De Maat MM, Ter Heine R, Mulder JW, et al.
Eur J Clin Pharmacol. 2003 Aug 12
 Abstract

Failure of a Short-Term Prednisone Regimen to Prevent Nevirapine-Associated Rash: A Double-Blind Placebo-Controlled Trial: The GESIDA 09/99 Study.
Knobel H, Miro JM, Domingo P, et al. 
J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):14-18.
 Abstract

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
Antinori A, Baldini F, Girardi E, et al
AIDS 2001 Aug 17;15(12):1579-81
Abstract
 
Hepatic Disorders
           
 
Proteomic Analysis of Serum and Urine of HIV-Monoinfected and HIV/HCV-Coinfected Patients Undergoing Long Term Treatment with Nevirapine.
 Wongtrakul J, Thongtan T, Roytrakul S, et al 
Dis Markers. 2014;2014:315824.
Abstract

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Tseng YT, Yang CJ, Chang SY, et al
Int J Infect Dis. 2014 Oct 10
 Abstract

The Interaction of CD4 T-Cell Count and Nevirapine Hepatotoxicity in China: A Change in National Treatment Guidelines may be Warranted.
 Zhang C, Wang W, Zhou M,  et al
J Acquir Immune Defic Syndr. 2013 Jan 2. [
 Abstract
ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique
.i Fusco D, Marazzi MC, Ciccacci C, D, et al
 Pharmacogenet Genomics. 2012 Sep 28
Abstract

Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.
 Chu KM, Manzi M, Zuniga I, et al
Int J STD AIDS. 2012 Jun;23(6):403-7.
 Abstract

Urgent liver transplantation for nevirapine-induced acute liver failure: Report of a case and review of the literature.
 Lopez-Delgado JC, Mendiluce RM, Pinol TS,  et al
 Ann Transplant. 2012 Mar 31;17(1):122-7..
 Abstract

FULL-TEXT ARTICLE
 Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity in Chinese Patients with HIV Infection.
Wang J, Kou H, Fu Q
PLoS One. 2011;6(10):e26739.
Paper

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
 Yuan J, Guo S, Hall D, et al
 AIDS. 2011 Apr 18.
Abstract

Nevirapine-associated hepatotoxicity was not predicted by CD4 count >/=250 cells/muL among women in Zambia, Thailand and Kenya.
 Peters P, Stringer J, McConnell MS,  et al
HIV Med. 2010 Jul 26
 Abstract

FULL-TEXT ARTICLE
 Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
 Kochar R, Nevah MI, Lukens FJ,  et al
World J Gastroenterol. 2010 Jul 14;16(26):3335-8.
 Paper

FULL-TEXT PDF ARTICLE
 Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
 Tchatchueng Mbougua JB, Laurent C, et al
BMC Public Health. 2010 Mar 1;10(1):105
 Paper

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
 Ciccacci C, Borgiani P, Ceffa S, Sirianni E,
Pharmacogenomics. 2010 Jan;11(1):23-31.
 Abstract

Hepatotoxicity in patients prescribed efavirenz or nevirapine.
 Brück S, Witte S, Brust J, et al
Eur J Med Res. 2008 Jul 28;13(7):343-8.
 Abstract
 
Risk for immune-mediated liver reactions by nevirapine revisited.
Medrano J, Barreiro P, Tuma P, et al
AIDS Rev. 2008 Apr-Jun;10(2):110-5.
 Abstract
 
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
 De Lazzari E, León A, Arnaiz JA, et al 
HIV Med. 2008 Apr;9(4):221-6.
 Abstract
 
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
 Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al
J Med Assoc Thai. 2008 Feb;91(2):159-65.
 Abstract
 
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
 Buyse S, Vibert E, Sebagh M, et al
Liver Transpl. 2006 Nov 28;12(12):1880-1882
Abstract
 
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/mul
 Manfredi R, Calza L.  
AIDS. 2006 Nov 14;20(17):2233-2236.
Abstract
 
Hepatic failure due to nevirapine treatment for HIV infection.
 Katzenstein TL.  
Ugeskr Laeger. 2005 Nov 14;167(46):4359.
 Abstract
 
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
 Sanne I, Mommeja-Marin H, Hinkle J, et al   
J Infect Dis. 2005 Mar 15;191(6):825-9.
 Abstract
 
Severe Leukopenia Associated with Mild Hepatotoxicity in an HIV Carrier Treated with Nevirapine.
 Shahar E, Krivoy N, Weltfriend S, Pollack S.
Jpn J Infect Dis. 2004 Oct;57(5):212-3.
 Abstract
 
The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests.
Almond LM, Boffito M, Hoggard PG, et al  
AIDS Res Hum Retroviruses. 2004 Jul;20(7):716-22.
Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
 
Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non-HIV-Infected Individuals.
 Patel SM, Johnson S, Belknap SM, et al 
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 120-125
 Abstract
 
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and
efavirenz-containing regimens in HIV-infected patients.
 Ena J, Amador C, Benito C, Fenoll V. et al 
Int J STD AIDS. 2003 Nov;14(11):776-81.
Abstract  
 
Case series of acute hepatitis in a non-selected group of HIV-infected patients on
nevirapine-containing antiretroviral treatment.
 De Maat MM, Ter Heine R, Van Gorp EC, et al
AIDS. 2003 Oct 17;17(15):2209-14
 Abstract  

Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine.
Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V
 HIV Clin Trials 2003 Mar-Apr;4(2):115-120
Abstract

Hepatotoxicity Following Nevirapine-Containing Regimens in HIV-1-Infected Individuals.
 De Maat M, Mathot R, Veldkamp A, et al.
Pharmacol Res 2002 Sep;46(3):295
 Abstract

FULL-TEXT ARTICLE
 Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: 
a case report.
 Gokengin D, Yamazhan T.
Ann Clin Microbiol Antimicrob 2002 Sep 16;1(1):1
 Paper

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy:  
Role of hepatitis C and B infections.
Sulkowski MS, Thomas DL, Mehta SH, et al.
Hepatology 2002 Jan;35(1):182-9
 Abstract 

Nevirapine-induced hepatitis: a case series and review of the literature.
 Piliero PJ, Purdy B.
AIDS Read 2001 Jul;11(7):379-82
 Abstract

Late onset hepatitis and prolonged deterioration in hepatic function associated with Nevirapine therapy.
 Clarke S., Harrington P., Condon C., et al
 Int Journal STD AIDS 2000:11:336-337
Abstract
 
 
 
Metabolic Disorders
   
 
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G, Zona S, Orlando G, et al
 Clin Drug Investig. 2011 Nov 1;31(11):759-67|
 Abstract

Morphological and Metabolic Components of Lipodystrophy in Various Nevirapine-Based Highly Active Antiretroviral Therapy (HAART) Regimens: A Cross-Sectional, Observational Study.
Guaraldi G, Zona S, Orlando G, et al
Clin Drug Investig. 2011 Sep 15
 Abstract
 
 
Renal Disorders
   
 
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Mauss S; Berger F; Schmutz, Guenther , et al  
 AIDS. 19(1):93-95, January 3, 2005.
 Abstract
 
 
Hypersensitivity
   
 
Rash and hepatitis within days of starting a new antiretroviral regimen: Nevirapine hypersensitivity, secondary syphilis or both?
 Saxon CJ, Helbert MR, Komolafe AJ, Higgins SP.
 Int J STD AIDS. 2013 Aug 8.
 Abstract

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population.
 Carr DF, Chaponda M, Jorgensen A,  et al
Clin Infect Dis. 2013 Jan 29
 Abstract

Nevirapine Hypersensitivity.
Popovic M, Shenton JM, Chen J,  
Handb Exp Pharmacol. 2010;196:437-451.
 Abstract

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
 Vitezica ZG, Milpied B, Lonjou C, et al 
AIDS. 2008 Feb 19;22(4):540-1.
Abstract
 
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
 Phillips E, Gutiérrez S, Jahnke N, et al 
AIDS. 2007 Jul 31;21(12):1561-156
 Abstract
 
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench
and back again.
 Martin A, Nolan D, Almeida CA, Rauch A, Mallal S. 
Pharmacogenomics. 2006 Jan;7(1):15-23.
Abstract
 
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.
Martin, AM,  Nolan, D, James I, et al    
AIDS. 19(1):97-99, January 3, 2005.
 Abstract

Hypersensitivity syndrome (DRESS) and meningoencephalitis  associated with nevirapine therapy.
Lanzafame M, Rovere P, et al.
Scand J Infect Dis 2001;33(6):475-6
Abstract

  
Mental Disorders
 		    
  Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Pedrol E, Llibre JM, Tasias M, et al  
 HIV Med. 2015 Aug 4
 Abstract

FULL-TEXT ARTICLE
 Neuropsychiatric complications of nevirapine treatment. 
 Wise MEJ K Mistry, S Reid. 
 BMJ 2002;324:879 ( 13 April )
 Paper
Meningoencephalitis
           
  Hypersensitivity syndrome (DRESS) and meningoencephalitis  associated with
nevirapine therapy.
Lanzafame M, Rovere P, et al.
Scand J Infect Dis 2001;33(6):475-6
Abstract		  
Oral Disorders
           
  Oral adverse effects due to the use of Nevirapine.
 Moura MD, Senna MI, Madureira DF, et al
J Contemp Dent Pract. 2008 Jan 1;9(1):84-90.
Abstract		  
 
Stevens-Johnson Syndrome/Toxic Epidermal Necrosis
 
 

 
FULL-TEXT ARTICLE
Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy.
 Kakande B, Isaacs T, Muloiwa R,  et al
 F1000Res. 2015 Jun 30;4:175.
 Paper

HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique.
Borgiani P, Di Fusco D, Erba F,  et al
Eur J Clin Pharmacol. 2013 Dec 10.
Abstract

Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
Dube N, Adewusi E, Summers R.
 S Afr Med J. 2013 May;103(5):322-5.
 Abstract

Nevirapine-induced Stevens-Johnson syndrome following HIV postexposure prophylaxis.
 Bannaga A, Rahama O, Barlow G. et al
BMJ Case Rep. 2013 Apr 25;2013.
 Abstract

Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient.
 Singh H, Kachhap VK, Kumar BN, Nayak K.
 Indian J Pharmacol. 2011 Feb;43(1):84-6.
 Abstract

Nevirapine-induced Stevens Johnson-syndrome and fulminant hepatic failure requiring liver transplantation.
 Jao J, Sturdevant M, Del Rio Martin J, et al
 Am J Transplant. 2010 Jul;10(7):1713-6
 Abstract

Fatal outcome of nevirapine-associated toxic epidermal necrolysis.
 Leng K, Lonsdorf A, Hartmann M.
Int J STD AIDS. 2008 Sep;19(9):642-3.
 Abstract
 
Nevirapine-induced Stevens-Johnson Syndrome in an HIV Patient.
 Jain V, Shome D, Natarajan S.  |
Cornea. 2008 Apr;27(3):366-367.
 Abstract

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, , et al. 
AIDS 2001 Sep 28;15(14):1843-1848
 Abstract

NVP Main Page Journal Main Page Main New/Newsworthy  Home Page

Nevirapine Journal Data
Adverse Events